Reference

Treatment of heaves

Treatment of heaves. Ciofalo, Vincent B. (USA ). U.S. Pat. Appl. Publ. US 2005020692 A1 27 Jan 2005,9 pp.In this article, certain chemicals are used. Some of their cas registry numbers are 34391-04-3 and 18559-94-9 (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61L009-04. ICS: A61K031-137. APPLICATION: US 2004-889906 13 Jul 2004. PRIORITY: US 2003-2003/PV489863 24 Jul 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 63 Methods and formulations are described for improving health and survival in animals suffering from heaves, encompassing the administration of the optically pure R(-)-isomer of albuterol, while minimizing or eliminating unwanted activities of the corresponding S(+)-isomer of albuterol. The invention is also directed to favorable oral administration of R(-)-albuterol to animals and to food compns. for animals suffering from heaves, comprising the optically active adrenergic beta-receptor agonist R(-)-albuterol. .

Treatment with (R)-albuterol has no advantage over racemic albuterol

All Rights Reserved. Treatment with (R)-albuterol has no advantage over racemic albuterol. Barnes, Peter J. (National Heart & Lung Institute, Imperial College, London, UK). American Journal of Respiratory and Critical Care Medicine, 174(9), 969-972 (English) 2006 American Thoracic Society. CODEN: AJCMED. ISSN: 1073-449X. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. The detrimental effects of B2-agonists in the treatment of asthma and the exptl. studies of albuterol enantiomers are discussed. The activity of normally used racemic albuterol resides in the R-enantiomer, whereas the (S)-enantiomer is inactive. 34391-04-3 and 18559-94-9 are also in the experiment. Some in vitro studies have demonstrated that the S-enantiomer may increase contractility of airway smooth muscle or mediator release, but this has not been confirmed in recent animal studies in vivo. More important, in patients with asthma, no consistent differences have been found with (R)-albuterol compared with-albuterol in bronchodilatation, bronchoprotection, or side effects, whereas (S)-albuterol is inactive with no documented adverse effects. (R)-albuterol is only currently available as a nebulized form, but in view of its clin. equivalence and considerably higher costs compared with the normal (R,S)-albuterol, this treatment cannot be recommended in any patient groups. .